Compare Amgen, Inc. (AMGN) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Hut 8 Corp — how do they compare? Amgen, Inc. trades at $356.92 (market cap $196.12B), while Hut 8 Corp trades at $96.15 (market cap $11.50B). The key difference: Amgen, Inc. is far larger — about 17.1× Hut 8 Corp's market cap, and Amgen, Inc. pays a 2.77% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| AMGN | HUT | |
|---|---|---|
Market Cap | $196.12B | $11.50B |
Sector | Health | Technology |
52-Week High | $388.16 | $133.02 |
52-Week Low | $271.18 | $19.45 |
Enterprise Value | $241.41B | $11.77B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
HUT trades at $102.22, down 3.77% over 24 hours, with a bearish technical signal and key support at $98. The company reported a net loss of $226.15 million in 2025 despite revenue growth, but recent earnings beats and a strategic pivot to AI infrastructure have driven positive analyst sentiment. Strong institutional backing is evident with $4.25 billion in project financing secured in June 2026.
Outlook remains speculative with high execution risk amid the business transition, though Wall Street consensus is bullish with a $135.63 price target. Key risks include sustained negative cash flow, competitive pressures in data centers, and reliance on successful AI project deployment to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
